Cargando…

Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer

BACKGROUND: The addition of bevacizumab (BEV) to standard doublet chemotherapy improves outcomes compared with chemotherapy alone in patients with metastatic colorectal cancer (mCRC). The OPAL study examined the effect of BEV+FOLFOXIRI followed by 5FU/LV and BEV maintenance on progression-free survi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stein, Alexander, Atanackovic, Djordje, Hildebrandt, Bert, Stübs, Patrick, Brugger, Wolfram, Hapke, Gunnar, Steffens, Claus-Christoph, Illerhaus, Gerald, Bluemner, Ernst, Stöhlmacher, Jan, Bokemeyer, Carsten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4578090/ https://www.ncbi.nlm.nih.gov/pubmed/26335608 http://dx.doi.org/10.1038/bjc.2015.299

Ejemplares similares

Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature
por: Stein, Alexander, et al.
Publicado: (2012)

Liver resection following FOLFOXIRI plus bevacizumab: a detailed pathological review
por: Walter, H, et al.
Publicado: (2013)

Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors
por: Sunakawa, Yu, et al.
Publicado: (2018)

FOLFOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer patients with unresectable liver metastases
por: Antoniotti, Carlotta, et al.
Publicado: (2022)

Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab
por: Loupakis, F, et al.
Publicado: (2013)

A Patient with Transverse Colon Cancer Complicated by Cowden Syndrome Administered FOLFOXIRI + Bevacizumab Therapy
por: Takehara, Kazuhiro, et al.
Publicado: (2023)

FOLFOXIRI plus bevacizumab as standard of care for first-line treatment in patients with advanced colon cancer
por: Cervantes, A., et al.
Publicado: (2023)

Cetuximab versus bevacizumab following prior FOLFOXIRI and bevacizumab in postmenopausal women with advanced KRAS and BRAF wild-type colorectal cancer: a retrospective study
por: Huang, Chunlong, et al.
Publicado: (2021)

Comment on ‘Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab'
por: Bibeau, F, et al.
Publicado: (2013)

Survival benefit and safety of the combinations of FOLFOXIRI ± bevacizumab versus the combinations of FOLFIRI ± bevacizumab as first-line treatment for unresectable metastatic colorectal cancer: a meta-analysis
por: Xu, Wei, et al.
Publicado: (2016)

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma
por: Lou, Emil, et al.
Publicado: (2013)

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trial
por: Aranda, Enrique, et al.
Publicado: (2020)

Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer
por: Loupakis, F, et al.
Publicado: (2011)

Reply: Comment on ‘Histopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumab'
por: Schirripa, M, et al.
Publicado: (2013)

Antitumor effects of bevacizumab in combination with fluoropyrimidine drugs on human oral squamous cell carcinoma
por: Itashiki, Yasutaka, et al.
Publicado: (2021)

Early evaluation of liver metastasis using spectral CT to predict outcome in patients with colorectal cancer treated with FOLFOXIRI and bevacizumab
por: Li, Shenglin, et al.
Publicado: (2023)

Clinical benefits of FOLFOXIRI combined with bevacizumab for advanced-stage primary signet ring cell carcinoma of the appendix: A case report
por: Huang, Nana, et al.
Publicado: (2023)

Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer
por: Miyo, Masaaki, et al.
Publicado: (2020)

Upfront Bevacizumab and Temozolomide or Fotemustine before Radiotherapy for Patients with Glioblastoma and Severe Neurological Impairment at Diagnosis
por: Bihan, Celina, et al.
Publicado: (2012)

Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
por: Bang, Yeong Hak, et al.
Publicado: (2021)

Single‐Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial)
por: García‐Alfonso, Pilar, et al.
Publicado: (2018)

Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO
por: Rossini, Daniele, et al.
Publicado: (2020)

A phase II study of FOLFOXIRI plus bevacizumab as initial chemotherapy for patients with untreated metastatic colorectal cancer: TRICC1414 (BeTRI)
por: Shinozaki, Katsunori, et al.
Publicado: (2020)

DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer
por: Cremolini, Chiara, et al.
Publicado: (2017)

FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial
por: Damato, Angela, et al.
Publicado: (2021)

AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer
por: Antoniotti, Carlotta, et al.
Publicado: (2020)

Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO
por: Rossini, D., et al.
Publicado: (2021)

A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11
por: Satake, Hironaga, et al.
Publicado: (2018)

Upfront DPYD Genotyping and Toxicity Associated with Fluoropyrimidine-Based Concurrent Chemoradiotherapy for Oropharyngeal Carcinomas: A Work in Progress
por: Desilets, Antoine, et al.
Publicado: (2022)

Correction: A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11
por: Satake, Hironaga, et al.
Publicado: (2018)

Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial
por: Suenaga, Mitsukuni, et al.
Publicado: (2020)

mFOLFOXIRI with or without bevacizumab for conversion therapy of RAS/BRAF/PIK3CA mutant unresectable colorectal liver metastases: the FORBES non-randomized phase II trial
por: Shen, Cailu, et al.
Publicado: (2022)

Bevacizumab for glioblastoma
por: Narita, Yoshitaka
Publicado: (2015)

Intravitreal bevacizumab
por: Khamar, Bakulesh M
Publicado: (2018)

Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial
por: Kuboki, Yasutoshi, et al.
Publicado: (2023)

A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
por: Hummel, Matthew, et al.
Publicado: (2021)

Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated – NIVACOR trial (GOIRC-03-2018)
por: Damato, Angela, et al.
Publicado: (2020)

Bevacizumab‐associated intestinal perforation and perioperative complications in patients receiving bevacizumab
por: Yoshimoto, Toshiaki, et al.
Publicado: (2020)

Cetuximab versus bevacizumab maintenance following prior 8-cycle modified FOLFOXIRI plus cetuximab in Asian postmenopausal women with treatment-naive KRAS and BRAF wild-type metastatic colorectal cancer
por: Chen, Baomin, et al.
Publicado: (2020)

Bevacizumab for the Treatment of Glioblastoma
por: Gil-Gil, Miguel J., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_8a85vmb4h1n5bq4gc961rdvaf5